Key clinical point: Mutations in Bruton’s tyrosine kinase (BTK) are associated with progression of chronic lymphocytic leukemia (CLL) in patients taking ibrutinib.
Major finding: Patients with BTK mutations were significantly more likely to experience CLL progression (P = .0005).
Study details: A real-world cohort of 30 CLL patients who were taking ibrutinib and who had undergone mutational profiling.
Disclosures: The research was supported by Sunesis Pharmaceuticals and the Force Hemato foundation. The researchers reported relationships with Janssen, Gilead, Roche, and AbbVie.
Quinquenel A et al. Blood. 2019 Jun 26. doi: 10.1182/blood.2019000854.